文献速递血栓与止血

慢性免疫性血小板减少症血小板功能再评估:血小板大小、抗αIIbβ3抗体及TPO受体激动剂的影响

Reevaluation of platelet function in chronic immune thrombocytopenia: impacts of platelet size, platelet-associated anti-αIIbβ3 antibodies and thrombopoietin receptor agonists.
PubMed 文献 · Br J Haematol · 2020-02-27

该研究用流式细胞术血小板聚集试验和PAC1/CD62P检测评估21例慢性ITP患者血小板功能,发现全门控法下聚集及活化标志物等效或增强,但尺寸校正法显示ADP、PAR1AP、胶原SRP诱导的PAC1及ADP诱导的CD62P受损。提示大血小板增多可能代偿功能缺陷,而TPO-RAs或抗αIIbβ3抗体与ADP诱导聚集受损相关。

要点

  • 全门控法显示cITP血小板聚集等效或增强,尺寸校正法揭示功能受损。
  • 大血小板增多可能代偿cITP血小板功能缺陷,使总体功能非劣。
  • TPO-RAs或抗αIIbβ3抗体患者ADP诱导聚集较对照受损。

核心结论

  • cITP血小板整体功能非劣可能源于大血小板数量增加代偿了尺寸校正后的功能受损。
  • 抗αIIbβ3自身抗体和/或TPO-RAs治疗可能对血小板功能有负面影响。

研究设计与样本

  • 研究纳入21例慢性ITP患者,采用流式细胞术血小板聚集试验(FCA)及PAC1/CD62P检测评估血小板功能。
  • PAC1/CD62P分析分别采用全门控法和尺寸校正法。

主要发现

  • FCA显示cITP组PMA或ADP诱导聚集与对照等效,PAR1AP诱导聚集增强。
  • 全门控法下cITP组PAC1或CD62P等效或增强。
  • 尺寸校正法显示cITP组ADP、PAR1AP、胶原SRP诱导的PAC1及ADP诱导的CD62P受损。
  • 与对照相比,TPO-RAs治疗或抗αIIbβ3抗体阳性患者ADP诱导聚集受损。

临床怎么用

  • 评估cITP血小板功能时需考虑血小板大小对检测结果的影响。
  • 对使用TPO-RAs或抗αIIbβ3抗体阳性的cITP患者应关注血小板功能受损可能。

局限性

  • 样本量较小(21例慢性ITP患者)。
  • 原文未报告长期临床结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platelet function of immune thrombocytopenia (ITP) has been controversial because of methodological problems associated with low platelet counts. In this study, we evaluated platelet function in 21 patients with chronic ITP (cITP) using the recently developed flow cytometry (FCM)-based platelet aggregation assay (FCA) along with a PAC1/CD62P assay. Since ITP platelets are larger than controls, whole platelets (whole gating method) and size-adjusted platelets (size-adjusted method) were analysed in the PAC1/CD62P via FCM. We found that: (i) aggregation was equivalent [phorbol myristate acetate (PMA) or adenosine diphosphate (ADP)-induced] or enhanced [protease-activated receptor 1-activating peptide (PAR1AP)-induced] in cITP compared with control by FCA; (ii) PAC1 or CD62P was also equivalent or enhanced in cITP in the whole gating method; and (iii) in sharp contrast, the size-adjusted method revealed that ADP-, PAR1AP-, and collagen synthetic liquid reactive peptide (SRP)-induced PAC1 and ADP-induced CD62P were impaired in cITP. These data suggested that an increase in the number of larger-sized platelets may compensate for the impaired platelet function of cITP, leading to non-inferiority of overall platelet function in cITP. Furthermore, we revealed that ADP-induced aggregation was impaired in the patients with thrombopoietin receptor agonists (TPO-RAs) or platelet-associated anti-αIIbβ3 antibodies compared with the control, suggesting that the presence of anti-αIIbβ3 autoantibodies and/or administration of TPO-RAs may have a negative impact on platelet function.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nishiura N, Kashiwagi H, Akuta K, et al. Reevaluation of platelet function in chronic immune thrombocytopenia: impacts of platelet size, platelet-associated anti-αIIbβ3 antibodies and thrombopoietin receptor agonists. Br J Haematol. 2020. PMID: 32106338. doi:10.1111/bjh.16439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。